SLN vs. ACAD, BHC, ARVN, DCPH, MRVI, RYTM, GERN, VERA, AMPH, and AGIO
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Arvinas (ARVN), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), Rhythm Pharmaceuticals (RYTM), Geron (GERN), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Silence Therapeutics (NASDAQ:SLN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.
Silence Therapeutics has higher earnings, but lower revenue than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals has a net margin of -0.21% compared to Silence Therapeutics' net margin of -131.44%. ACADIA Pharmaceuticals' return on equity of -0.41% beat Silence Therapeutics' return on equity.
Silence Therapeutics currently has a consensus target price of $57.25, indicating a potential upside of 182.02%. ACADIA Pharmaceuticals has a consensus target price of $28.94, indicating a potential upside of 89.13%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Silence Therapeutics is more favorable than ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals received 852 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 73.53% of users gave Silence Therapeutics an outperform vote while only 72.96% of users gave ACADIA Pharmaceuticals an outperform vote.
98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Silence Therapeutics. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 2 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.30 beat ACADIA Pharmaceuticals' score of 0.17 indicating that Silence Therapeutics is being referred to more favorably in the media.
Silence Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
Summary
Silence Therapeutics and ACADIA Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
